Dr. Ashapurna Borgohain

Dr.A. GIRIDHAR, Dr. G. MAHESH, DR. VINEET SHAH

Abstract

A retrospective study of 46 eyes of 44 patients with type 1 choroidal neovascularization(CNV) & polypoidal choroidal vasculopathy(PCV) poorly responsive to previous anti-VEGF therapy was conducted. Patients switched to Brolucizumab on ProReNata regime & followed up for ≥ 6months were included.Mean injections received before switch was 8.3±7.6.Average brolucizumab injections given were 2.13±1.5 during a mean follow up period of 8.1±5.1months. Central macular thickness reduced from 417.3 ± 127.7 to 343.2 ±171.1µm at 6 months(P < 0.001).Mean reduction of Pigment Epithelial detachment maximum height was 314.7±326.3 to 246.9±216.1µm at 6months (p< 0.001).BCVA gain was not statistically significant(p=0.618). Subretinal fluid was present in 67.9% of cases pre-injection. Complete resolution was seen in 49.1% at 1 month. At 6months follow up 26.4% remained dry. Recurrence was seen at an average of 4.65 months. Brolucizumab was effective in poorly responsive CNV & reducing number of injections.

Full Text